Form 4 for BLFS BIOLIFE SOLUTIONS INC

Accepted 2021-11-03 00:00:00 ET · period of report 2021-09-01 · accession 0000919574-21-006570 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2021-11-03	2021-09-01	BLFS	Casdin Eli	10%	J - Other	—	+126.2K	7.57M	+2%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, par value $.001 per share	2021-09-01	J	A	126,185	—	7,566,292	D	—	—	(F1) The reported securities were received by Casdin Partners Master Fund, L.P. (the "Master Fund") upon closing of the merger between Sexton Biotechnologies, Inc. ("Sexton") and the Issuer with approximately 10% of the amount deposited into an escrow account for indemnification and post-closing purchase price adjustments. The foregoing description of the merger does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on September 8, 2021, which is incorporated by reference. (F2) The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.